Combined gene for second-generation sequencing of multiple myeloma, application of combined gene and sequencing method based on combined gene

Abstract

The invention discloses a combined gene for second-generation sequencing of multiple myeloma, application of the combined gene and a sequencing method based on the combined gene. The combined gene comprises 92 gene combinations, a gene detection area, a sequencing process and sequencing result analysis. The novel gene sequencing combination provided by the invention comprises MM-related virulence genes, drug-resistant genes, bone disease genes and other high-frequency genes, so that the technical scheme has the characteristics of universality, sensitivity and accuracy, overcomes the defects of conventional genetic detection, explores the occurrence and development of diseases from the molecular level and provides potential therapeutic targets for drug-resistant patients. Therefore, an important reference basis is provided for clinical treatment decision making, and individualized and precise treatment of the MM is finally achieved.

Description

technical field [0001] The invention belongs to the field of clinical application of second-generation gene sequencing technology, and in particular relates to a combined gene for second-generation sequencing of multiple myeloma, its application and a sequencing method based on it. Background technique [0002] Multiple myeloma (Multiple Myeloma, MM) is a malignant tumor derived from plasma cells, and its incidence rate ranks second among hematological malignancies. Although the application of proteasome inhibitors (such as bortezomib, etc.) and new immunomodulators (such as lenalidomide, etc.) have greatly improved the survival of patients, it is still an incurable disease. Previous studies have found that the occurrence and development of MM are related to the abnormal expression of multiple oncogenes and proto-oncogenes, including Bcl-2, C-myc, RAS, P53, RB1, etc., but so far, no gene has been found to be involved in all MM All patients had abnormalities, which suggested...

AI Technical Summary

Problems solved by technology

[0004] Reported research institutions have set up different gene combinations such as GEP70, SKY92, UAMS70, UAMS80, IFM15, and HM19, etc., but different research NGS detection methods, included genes, and detection populations are quite different, resulting in large bias in research results. At the same time, because most of the tests do not perform plasma cell sorting, the detection rate of mutations is low, which limits the promotion of clinical applications.

Compared with the currently applied MM-related target gene detection patent (CN 111575375 A), the detection rate of MM high-frequency mutation gene KRAS / NRAS / BRAF is only 27.78%, and the detection rate of multiple genes is 0, which is inconsistent with literature reports

Images